Author

Mostafa E. Mohamed

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

OpenAlex ID: A5021980048

Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

2024 · Binod Dhakal, Michael Slade, et al. · Blood

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in-Class Transition ( iCT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

2023 · Hans C. Lee, June Li, et al. · Blood

Works count: 2

Citation count:

H-index:

I10-index: